Drew J. Winston
Experienced in Sepsis

Dr. Drew J. Winston

Infectious Disease
10833 Leconte Ave, Ucha Medical Center Dept Of Medicine Room 42 121 Chs, 
Los Angeles, CA 
49 Years of Experience
Experienced in Sepsis
10833 Leconte Ave, Ucha Medical Center Dept Of Medicine Room 42 121 Chs, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Drew Winston is an Infectious Disease provider in Los Angeles, California. Dr. Winston has been practicing medicine for over 49 years and is rated as an Experienced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Cytomegalovirus Infection, Shingles, Cytomegalic Inclusion Disease, and Chickenpox.

His clinical research consists of co-authoring 39 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles in the study of Sepsis.

Specialties
Infectious Disease
Licenses
Internal Medicine in CA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

10833 Leconte Ave, Ucha Medical Center Dept Of Medicine Room 42 121 Chs, Los Angeles, CA 90024

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Enrollment Status: No_longer_available
Publish Date: March 14, 2022
Intervention Type: Drug
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients
Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients
Enrollment Status: Completed
Publish Date: August 26, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia
Enrollment Status: Withdrawn
Publish Date: July 21, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.
Enrollment Status: Terminated
Publish Date: May 17, 2019
Intervention Type: Drug
View 5 Less Clinical Trials

39 Total Publications

Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay.
Real-world clinical impact of plasma cell-free DNA metagenomic next-generation sequencing assay.
Journal: Infection control and hospital epidemiology
Published: January 30, 2025
Similar Doctors
Distinguished in Sepsis
Dr. Minghsun Liu
Infectious Disease
Distinguished in Sepsis
Dr. Minghsun Liu
Infectious Disease

Minghsun Liu, M.D., Ph.d., P.C.

11103 Venice Blvd, 
Los Angeles, CA 
 (3.8 miles away)
310-734-8526
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Minghsun Liu is an Infectious Disease provider in Los Angeles, California. Dr. Liu is rated as an Advanced provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Hospital-Acquired Pneumonia, Pneumonia, and Lymphangitis. Dr. Liu is currently accepting new patients.

Distinguished in Sepsis
Dr. Jean-pierre E. Antaki
Infectious Disease
Distinguished in Sepsis
Dr. Jean-pierre E. Antaki
Infectious Disease

Antaki And Associates Infectious Disease Medical Group Inc

801 S Chevy Chase Dr, Suite 101, 
Glendale, CA 
 (12.6 miles away)
323-242-5299
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jean-pierre Antaki is an Infectious Disease provider in Glendale, California. Dr. Antaki has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Pneumonia, Hospital-Acquired Pneumonia, Sepsis, and COVID-19.

Distinguished in Sepsis
Dr. Alan Nazarian
Infectious Disease
Distinguished in Sepsis
Dr. Alan Nazarian
Infectious Disease
108370 Burbank Blvd, 
Tarzana, CA 
 (8.7 miles away)
818-532-8120
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Alan Nazarian is an Infectious Disease provider in Tarzana, California. Dr. Nazarian is rated as a Distinguished provider by MediFind in the treatment of Sepsis. His top areas of expertise are Sepsis, Hospital-Acquired Pneumonia, Arachnoiditis, and Pneumonia. Dr. Nazarian is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Winston's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile